ArticleAnnals of the rheumatic diseases2018
The EuroMyositis registry: an international collaborative tool to facilitate myositis research.
Article in Annals of the rheumatic diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 133 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
133 citing papers in PubMed, 5 syntheses or guidelines pooled it, 265 citations in OpenAlex.
- Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach From the Writing Committee of the American Society for Apheresis: The Tenth Special Issue.Journal of clinical apheresis · 2026Guideline
- Associations between anti-mitochondrial antibodies and cardiac involvement in idiopathic inflammatory myopathy patients : A systematic review and meta-analysis.Zeitschrift fur Rheumatologie · 2024Pooled it
- Diagnostic delay of myositis: an integrated systematic review.Orphanet journal of rare diseases · 2022Pooled it
- Defining anti-synthetase syndrome: a systematic literature review.Clinical and experimental rheumatology · 2022Pooled it
- A systematic review and meta-analysis to inform cancer screening guidelines in idiopathic inflammatory myopathies.Rheumatology (Oxford, England) · 2021Pooled it
- Comparison of Three Immunoassays for the Detection of Myositis Specific Antibodies.Frontiers in immunology · 2019Trial
- Flares and definition of worsening in inflammatory myopathies: a narrative review of the literature.Rheumatology (Oxford, England) · 2026Review
- Clinicopathological and serological spectrum of idiopathic inflammatory myopathies: Experience from a neuromuscular referral center in Cyprus.Journal of neuromuscular diseases · 2026Article
- Evaluation of the prognostic value of visual and quantitative CT analysis in myositis-associated interstitial lung disease.RMD open · 2026Article
- Review
- Clinical characteristics and long-term prognosis of anti-MDA5-positive dermatomyositis: a comparative study across age groups.Orphanet journal of rare diseases · 2026Article
- The Spectrum of Cutaneous Manifestations in Dermatomyositis: A Comprehensive Review.Journal of clinical medicine · 2026Review
- Advances in Biomarkers and Therapeutic Targets for Idiopathic Inflammatory Myopathies Related Lung Disease.Clinical reviews in allergy & immunology · 2026Review
- Clinical profiles associated with rapidly progressive interstitial lung disease in antisynthetase syndrome: A multicentric cohort study (TYPASS study).Journal of internal medicine · 2026Article
- Registry of idiopathic inflammatory myopathies (REMAS) from nine Brazilian research centers linked to tertiary care and teaching hospitals.Advances in rheumatology (London, England) · 2026Article
- A five-factor risk-stratification model for cancer-associated myositis in idiopathic inflammatory myopathies and stage-specific survival analysis: a multicentre Japanese MYKO cohort study.Frontiers in immunology · 2026Article
- Pulmonary cystic destruction in systemic sclerosis and antisynthetase syndrome associated non-specific interstitial pneumonitis: a case series of a novel radiological phenotype.Rheumatology advances in practice · 2026Article
- Myocardial involvement in inflammatory myopathies: from subclinical disease to life-threatening myocarditis.Expert review of clinical immunology · 2026Review
- Unilateral lower limb cellulitis-like edema as an atypical cutaneous manifestation of antisynthetase syndrome: a case report and targeted literature review.Frontiers in medicine · 2026Article
- Immune Myositis Complicating Follicular Lymphoma: Case Report.Reports (MDPI) · 2025Article
73 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
28 authors at 19 institutions in 14 countries.
Funding
Abstract
aimsThe EuroMyositis Registry facilitates collaboration across the idiopathic inflammatory myopathy (IIM) research community. This inaugural report examines pooled Registry data.
methodsCross-sectional analysis of IIM cases from 11 countries was performed. Associations between clinical subtypes, extramuscular involvement, environmental exposures and medications were investigated.
resultsOf 3067 IIM cases, 69% were female. The most common IIM subtype was dermatomyositis (DM) (31%). Smoking was more frequent in connective tissue disease overlap cases (45%, OR 1.44, 95% CI 1.09 to 1.90, p=0.012). Smoking was associated with interstitial lung disease (ILD) (OR 1.32, 95% CI 1.06 to 1.65, p=0.013), dysphagia (OR 1.43, 95% CI 1.16 to 1.77, p=0.001), malignancy ever (OR 1.78, 95% CI 1.36 to 2.33, p<0.001) and cardiac involvement (OR 2.40, 95% CI 1.60 to 3.60, p<0.001).Dysphagia occurred in 39% and cardiac involvement in 9%; either occurrence was associated with higher Health Assessment Questionnaire (HAQ) scores (adjusted OR 1.79, 95% CI 1.43 to 2.23, p<0.001). HAQ scores were also higher in inclusion body myositis cases (adjusted OR 3.85, 95% CI 2.52 to 5.90, p<0.001). Malignancy (ever) occurred in 13%, most commonly in DM (20%, OR 2.06, 95% CI 1.65 to 2.57, p<0.001).ILD occurred in 30%, most frequently in antisynthetase syndrome (71%, OR 10.7, 95% CI 8.6 to 13.4, p<0.001). Rash characteristics differed between adult-onset and juvenile-onset DM cases ('V' sign: 56% DM vs 16% juvenile-DM, OR 0.16, 95% CI 0.07 to 0.36, p<0.001). Glucocorticoids were used in 98% of cases, methotrexate in 71% and azathioprine in 51%.
conclusionThis large multicentre cohort demonstrates the importance of extramuscular involvement in patients with IIM, its association with smoking and its influence on disease severity. Our findings emphasise that IIM is a multisystem inflammatory disease and will help inform prognosis and clinical management of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.